SZXJ Medical Scientific Corporation is the leading supplier of minimally invasive interventional medical devices to treat cardiovascular diseases. The company specializes in R&D, manufacture and sales, and its high-quality, innovative, proprietary products are extensively marketed in more than 100 countries by over 300 distributors. At present, the company is the world second largest supplier (and the largest among BRIC countries) of occluders to treat congenital heart diseases and the second largest supplier of aortic repair device in Asia Pacific.
SZXJ has setup subsidiaries and sales offices in Hong Kong, India, Netherland, France, Russia, America, Greece, Beijing, Shanghai, Guangzhou and etc.
In 2008, the company was successfully listed on the Hong Kong Stock Exchange with the market cap over 10 billion HKD.
As a result of its pursuit for quality and innovation, the quality system of SZXJ was accredited by the DEKRA in EU (ISO13485: 2003), and passed inspection of Good Manufacturing Practice for Chinese Medical Devices. The company was rated as a National High- Tech Enterprise in 2008, and has obtained scientific research qualifications such as National Post-Doctoral Research Center, National and Local Joint Engineering Laboratory, etc. The company has also undertaken more than 50 government research projects, including the National Key Technology Research and Development Program of China under the “Tenth Five-Year Plan, the National Basic Research Program (973 Program) and the National High Technology Research and Development Program of China (863 Program). At the end of 2017, 6 products of the company have been approved as innovative medical devices by China Food and Drug Administration (CFDA).
SZXJ is a leader in the aortic interventional market. It ranks among the top three in China in terms of stent implantation. From 2021, a number of blockbuster products will be launched one after another. From 2021, SZXJ will have multiple blockbuster products on the market, and the product pipeline will cover the entire aorta. A number of aortic stent products under research are global or domestic original creations, including a variety of blockbuster products. SZXJ will greatly enhance its competitiveness and is expected to penetrate the indications that previously could only use open surgery. The successive launch of new products will support LifeTech's growth, forming a three-part world of SZXJ, SHXM and Medtronic.
In terms of peripheral intervention layout, both the stent and the medicine ball enter the green channel of the device. SZXJ's vena cava filter is already the first brand in China and will gradually start the process of domestic substitution.
Products
Occluders
Stent Graft System
Delivery System
Vena Cava Filter
Vascular Plug
Sizing Ballon
Dilator
Snare System
Congenital occluder and left atrial appendage occluder
Xianxin occluders are growing steadily both at home and abroad. The existing three-generation products are used to form an echelon to meet different market needs. Both absorbable occluders and PFO occluders have entered the green channel and are expected to be on the market around 2022-23. The continuous improvement of the product line will promote the steady growth of products at home and abroad. The main advantages are as follows:
1. China's CHD (congenital heart disease) interventional treatment level is leading, and import substitution has basically been completed, but the penetration rate is still not high.
2. SZXJ occupies a leading position in the industry.
3. The annual sales growth rate of Xianxin occluder is 15-20%, and the sales of products in Europe are also growing rapidly.
4. SZXJ continues to innovate materials, improve functions, and form a complete product portfolio and echelon after it goes on the market.
The iron-based absorbable vascular stent project was launched in 2006, and it has been continuously developed for more than 13 years. It took 3 years to screen the technology path and select iron-based materials to make the absorbable stent. The first batch of the entire project includes three products: absorbable coronary stent (IBS), absorbable lung vascular stent (IBSAngel) and absorbable subknee vascular stent (IBSTitan).